Compare Abbott Laboratories (ABT) vs American Superconductor Corporation (AMSC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs American Superconductor Corporation — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while American Superconductor Corporation trades at $36 (market cap $1.72B). The key difference: Abbott Laboratories is far larger — about 97.1× American Superconductor Corporation's market cap, and Abbott Laboratories pays a 2.63% dividend while American Superconductor Corporation pays none. Which is the better fit depends on your goals.
| ABT | AMSC | |
|---|---|---|
Market Cap | $166.94B | $1.72B |
Sector | Health | Technology |
52-Week High | $136.62 | $66.68 |
52-Week Low | $82.57 | $25.95 |
Enterprise Value | $193.69B | $1.59B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
AMSC trades at $38.13, up 2.75% today, but technical indicators signal bearish momentum with selling pressure across moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.30 surpassing expectations of $0.19. Revenue grew 34% year-over-year to $299.2 million in fiscal 2025, while net income margin expanded significantly to 44.73%. However, negative cash flow of -$6.90 million in 2025 and high EV/EBITDA of 71.09 raise valuation concerns.
The outlook remains mixed with analyst consensus leaning bullish (53% buy ratings) but technical weakness suggesting near-term pressure. Key opportunities include strong backlog growth (up 40% to $280 million) and expanding AI/energy infrastructure demand. Risks include acquisition-driven revenue growth, high valuation multiples, and insider selling activity. Earnings growth remains the primary catalyst for sustained upside momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About American Superconductor Corporation
AMSC provides energy technology solutions for smarter and cleaner power grids. It offers wind turbine electronic controls and advanced grid systems that enhance the reliability and efficiency of renewable energy networks.
Read more on AMSC →
